Methylquinazolinone derivatives

Patent metadata

Field	Value
Publication number	US-2024174621-A1
Application number	US-202318525536-A
Country	US
Kind code	A1
Filing date	Nov 30, 2023
Priority date	Dec 10, 2019
Publication date	May 30, 2024
Grant date	—

Abstract

The invention provides, for example, a novel compound having the general formula (I):or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.

First claim

1 . A compound of formula (I):

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein the compound is the compound of formula (I):

3 . The compound of claim 1 , wherein the compound is a compound of formula (Ia):

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein the compound is a compound of formula (Ib):

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 , wherein the compound is a compound of formula (Ia):

6 . The compound of claim 1 , wherein the compound is a compound of formula (Ib):

7 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

8 . The pharmaceutical composition of claim 7 , wherein the compound is a compound of formula (Ia):

or a pharmaceutically acceptable salt thereof.

9 . The pharmaceutical composition of claim 7 , wherein the compound is a compound of formula (Ib):

or a pharmaceutically acceptable salt thereof.

10 . A method for the treatment of cancer, the method comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

11 . The method of claim 10 , wherein the cancer is selected from a group consisting of thyroid cancer, colorectal cancer, brain cancer, melanoma and non-small cell lung cancer (NSCLC).

12 . The method of claim 10 , wherein the cancer is a BRAF mutant cancer.

13 . The method of claim 12 , wherein the BRAF mutant cancer is V600E mutated BRAF cancer.

14 . The method of claim 12 , wherein the BRAF mutant cancer is V600K mutated BRAF cancer.

15 . The method of claim 10 , wherein the compound is a compound of formula (Ia):

or a pharmaceutically acceptable salt thereof.

16 . The method of claim 10 , wherein the compound is a compound of formula (Ib):

or a pharmaceutically acceptable salt thereof.

17 . A process for the preparation of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, the process comprising reacting a compound of formula (B1):

with a compound of formula (B2):

in the presence of a base.

18 . The process of claim 17 , wherein the base is cesium carbonate.

Assignees

• Hoffmann La Roche

Inventors

• Dolente Cosimo
• Hewings David Stephen
• Hunziker Daniel
• Krummenacher Daniela
• Pettazzoni Piergiorgio Francesco Tommaso
• Wichmann Juergen

Classifications

• C07D207/48

  Sulfur atoms · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07D405/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D403/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D239/88 Primary

  Oxygen atoms · CPC title